Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Thérèse Valat"'
Autor:
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Thérèse Valat, Masato Murakami, Stephan Ruetz, Daniel A Guthy, Caroline Rynn, Michael R Jensen, Marion Wiesmann, Joerg Kallen, Pascal Furet, François Gessier, Philipp Holzer, Keiichi Masuya, Jens Würthner, Ensar Halilovic, Francesco Hofmann, William R Sellers, Diana Graus Porta
Publikováno v:
eLife, Vol 5 (2016)
Externí odkaz:
https://doaj.org/article/29da49791cad4fb8895cef0bf7f76fea
Autor:
Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Thérèse Valat, Masato Murakami, Stephan Ruetz, Daniel A Guthy, Caroline Rynn, Michael R Jensen, Marion Wiesmann, Joerg Kallen, Pascal Furet, François Gessier, Philipp Holzer, Keiichi Masuya, Jens Würthner, Ensar Halilovic, Francesco Hofmann, William R Sellers, Diana Graus Porta
Publikováno v:
eLife, Vol 4 (2015)
Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53–HDM2 inhibitor NVP-CGM09
Externí odkaz:
https://doaj.org/article/c47da66860c643148939459e36ed4a7e
Autor:
Stephane Ferretti, Stephan Ruetz, Diana Graus Porta, Daniel Guthy, Hans Bitter, Pascal Furet, Ensar Halilovic, Keiichi Masuya, Caroline Rynn, Swann Gaulis, Francesco Hofmann, Joerg Kallen, Thérèse Valat, Marion Wiesmann, William R. Sellers, Michael Rugaard Jensen, Jens Würthner, Masato Murakami, Philipp Holzer, Sébastien Jeay, Moriko Ito, François Gessier
Publikováno v:
eLife, Vol 4 (2015)
eLife
eLife
Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53–HDM2 inhibitor NVP-CGM09
Autor:
Joanna Lisztwan, Thérèse Valat, Alain De Pover, Pascal Furet, Keiichi Masuya, Joerg Kallen, Patrick Chène
Publikováno v:
Bioorganicmedicinal chemistry letters. 22(10)
Disrupting the interaction between the p53 tumor suppressor and its regulator MDM2 is a promising therapeutic strategy in anticancer drug research. In our search for non peptide inhibitors of this protein–protein interaction, we have devised a liga
Autor:
Edgar Jacoby, Philipp Holzer, Joerg Kallen, Tobias Gabriel, Marc Lang, François Gessier, Stephane Ferretti, Keiichi Masuya, Pascal Furet, Sébastien Jeay, Caroline Rynn, Francesco Hofmann, Carole Pissot-Soldmann, Stefan Stutz, Nicole Buschmann, Thérèse Valat, Joerg Berghausen, Stephan Ruetz
Publikováno v:
Cancer Research. 74:DDT01-01
The antiproliferative transcriptional activity of the p53 tumor suppressor is inhibited by the binding of its transactivation domain to the regulator protein Mdm2. Overexpression of Mdm2 or amplification of its gene, leading to a loss of p53 function
Autor:
Tobias Gabriel, Thérèse Valat, Frédéric Baysang, Joerg Kallen, Philipp Holzer, Carole Pissot-Solderman, Pascal Furet, Keiichi Masuya, Sébastien Jeay, Patrick Chène, Geneviève Albrecht, Francesco Hofmann, Dirk Erdmann, Stefan Stutz, François Gessier, Nicole Buschmann
Publikováno v:
Cancer Research. 74:1798-1798
An effective strategy to restore p53 activity in cancer cells containing wild type p53 is to inhibit the Mdm2-p53 protein-protein interaction (PPI). NVP-CGM097 is a novel PPI inhibitor under evaluation in a Phase I clinical trial. It binds to the p53
Autor:
Masato Murakami, Joerg Kallen, Edgar Jacoby, Tobias Gabriel, Marc Lang, Marion Wiesmann, Dario Sterker, Nicole Buschmann, Francesco Hofmann, Diana Graus-Porta, François Gessier, Sébastien Jeay, Caroline Rynn, Dirk Erdmann, Stefan Stutz, Joanna Lisztwan, Keiichi Masuya, Carole Pissot-Soldermann, Michael Rugaard Jensen, Patrick Chène, Stephane Ferretti, Philipp Holzer, Robert Cozens, Pascal Furet, Thérèse Valat, Joerg Berghausen, Moriko Ito, Stephan Ruetz
Publikováno v:
Cancer Research. 74:1797-1797
Activation of p53 by blocking the p53-Mdm2 interaction using non-peptidic small-molecule inhibitors is being pursued as a promising cancer therapeutic strategy. In the present study, we show the identification of NVP-CGM097, a novel, highly optimized
Publikováno v:
Périodiques Scientifiques en Édition Électronique.
SUMMARY The Kel Kummer tribe, a leading one in the Ioullemmeden Tuareg of Southern Sahara, was founded in the XVIIth century after various quarrels for succession. Since then, due to its attitude, it has remained apart from the other Tuareg tribes an